Genetically Modified, Cord Blood Derived Natural Killer Cell Therapy for High Grade Pediatric Brain Tumors |
Children’s Research Institute / Conrad Russell Cruz, MD, PhD |
'A' Award Grants |
2015 |
District of Columbia |
Circulating Tumor Biomarkers: New Paradigms for Management of Neuroblastoma |
University of Chicago / Mark Applebaum, PhD |
'A' Award Grants |
2021 |
Illinois |
Investigating the Role of Genetic and Epigenetic Variation in Risk of Childhood Acute Lymphoblastic Leukemia in Down Syndrome |
University of California San Francisco / Adam de Smith, Ph.D. |
'A' Award Grants |
2014 |
California |
Mechanisms of PAX3-FOXO1 and HES3 Cooperation in Rhabdomyosarcoma |
Nationwide Children’s Hospital / Genevieve Kendall, PhD |
'A' Award Grants |
2018 |
Ohio |
Prognostic and Therapeutic Significance of Stem Cell Heterogeneity in AML |
Fred Hutchinson Cancer Research Center / Roland Walter, MD, PhD |
'A' Award Grants |
2012 |
Washington |
Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma |
University of California San Francisco / William Clay Gustafson, MD, PhD |
'A' Award Grants |
2011 |
California |
Epigenetic Modifiers as Therapeutic Targets in Pediatric T-cell Acute Lymphoblastic Leukemia |
Washington University / Grant Challen, PhD |
'A' Award Grants |
2012 |
Missouri |
The Role of Inherited MLL3 Single Nucleotide Variants and Fetal Epigenetic Programming in Infant Leukemogenesis |
Washington University / Jeffrey Magee, MD/PhD |
'A' Award Grants |
2016 |
Missouri |
Exploiting the Differentiation Potential of Pediatric High-Grade Glioma to Discover Novel Therapeutic Opportunities |
Dana-Farber Cancer Institute / Mariella Filbin, MD/PhD |
'A' Award Grants |
2019 |
Massachusetts |
Rational Combination Therapy of AML |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD, PhD |
'A' Award Grants |
2013 |
New York |